Please assess the completion status of the following clinical trial:

Trial Title: The FIGHT-RP1 Study

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~All subjects must meet the following criteria to be eligible for study entry:~* Signed informed consent and authorization of use and disclosure of protected health information~* Age \>18 years~* Patients diagnosed with RP by the investigators, based on clinical phenotype and diagnostic tests~Exclusion Criteria:~Subjects who meet any of the following criteria will be ineligible for study entry:~* Patients with concurrent retinal pathologies that result in vision loss, including but not limited to retinal vein occlusion, diabetic retinopathy and neovascular age-related macular degeneration. If one eye does not have any retinal pathology other than RP, it may be enrolled in the study.~* Patients with uncontrolled arterial hypertension defined as diastolic blood pressure \> 95 mm Hg or systolic blood pressure \> 160 mm Hg despite medical therapy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Experimental Arm (carbonyl content >0.6, GSH/GSSG <3) (Type: EXPERIMENTAL): Subjects with RP will be enrolled in the experimental arm if they have a high carbonyl content (\>0.6) and a reduced GSH/GSSG ratio (\<3.0) in the aqueous.
- Exploratory Arm (carbonyl content <0.6, GSH/GSSG >3) (Type: EXPERIMENTAL): Subjects with RP who don't have a high carbonyl content (\>0.6) and a reduced GSH/GSSG ratio (\<3.0) but otherwise are good candidates for the study will be enrolled in the exploratory arm.

Based on this trial design, predict the completion outcome and termination type (if applicable).